InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Nasus Pharma Ltd

NSRX Clue Score41
Israel Fiscal year ends December CIK 0002029039
$3.51 -3.31% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.51 −54.71% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 13 Aug 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Operating income−1.1Net income−1.1EPS, diluted−0.20Fiscal year 2024Operating income−1.1Net income−1.5EPS, diluted−0.22Fiscal year 2025Revenue1,235.0Operating income−4.9Net income−5.9EPS, diluted−0.72
FY2023FY2024FY2025
Revenue n/a n/a 1,235.0
Growth
Operating income −1.1 −1.1 −4.9
Net income −1.1 −1.5 −5.9
Growth
EPS, diluted −0.20 −0.22 −0.72
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Fiscal year 2024Fiscal year 2025Operating margin−0.4%Net margin−0.5%Free cash flow margin−0.4%
FY2023FY2024FY2025
Operating margin n/a n/a −0.4%
Net margin n/a n/a −0.5%
Free cash flow margin n/a n/a −0.4%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−1.0Fiscal year 2024Operating cash flow−0.7Fiscal year 2025Operating cash flow−4.9Capital expenditure−0.0Free cash flow−4.9
FY2023FY2024FY2025
Operating cash flow −1.0 −0.7 −4.9
Capital expenditure n/a n/a −0.0
Free cash flow n/a n/a −4.9
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash0.2Shareholders’ equity−3.8Fiscal year 2024Cash0.3Shareholders’ equity−3.2Fiscal year 2025Cash1.2Shareholders’ equity2.8
FY2023FY2024FY2025
Cash 0.2 0.3 1.2
Shareholders’ equity −3.8 −3.2 2.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a n/a 1,235.0
Growth
0.6 0.3 2.2
0.6 0.7 2.7
−1.1 −1.1 −4.9
Growth
−1.1 −1.5 −5.9
Growth
Per share
−0.15 −0.22 −0.72
−0.20 −0.22 −0.72
Growth
6.9 7.0 8.0
7.1 7.0 8.0
Growth −0.4% +14.0%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 3 of 3 years on file.